在阿尔茨海默病中协调陶正子发射断层扫描:CentTauR尺度和联合传播模型
Antoine Leuzy1,2,3, Lars Lau Raket1,4, Victor L Villemagne5,6,7
1Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.
概括
一个新的联合传播模型 (JPM) 协调了不同标记器的定子发射断层扫描 (PET) 量化,创建了一个称为CenTauRs (CTR) 的通用尺度. 这种方法提供了更准确的阿尔茨海默病 (AD) tau-PET数据比较.
科学领域:
- 神经成像是一种神经成像.
- 阿尔茨海默氏症疾病研究研究
- 生物统计学 生物统计学
背景情况:
- 目前来自阿尔茨海默病 (AD) 患者的tau-PET数据很难比较,原因是跟踪剂,设备和分析的差异.
- 这种异质性限制了跨研究结果数据的有意义的组合和比较.
研究的目的:
- 开发和验证一种方法来协调不同tau-PET标记物的定量测量.
- 为tau-PET量化建立一个通用尺度,使AD研究中的标准化数据比较成为可能.
主要方法:
- 利用了来自五个群体的头对头数据,其中包括针对AD tau病理的tau PET放射追踪器.
- 测试了一种联合传播模型 (JPM) 以协调量化,将新的单位定义为CenTauRs (CTR).
- 将JPM性能与线性回归方法进行比较,类似于粉样蛋白PET百度粉样蛋白尺度.
主要成果:
- 在各种大脑区域的CTR值之间发现了强烈的线性关系.
- 采用JPM方法的CTR估计比使用线性回归方法更准确.
- 与线性回归方法相比,JPM在协调tau PET量化方面表现优越.
结论:
- 初步发现支持JPM作为一种可行的方法,用于创建通用tau-PET量化量表.
- 建议在未来的AD研究中开发和采用这种协调规模 (CTR).
- 这种标准化将有助于对阿尔茨海默氏症的TAU PET数据进行更强大的比较和元分析.
相关概念视频
01:29Positron Emission Tomography
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...